Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03911973 · ClinicalTrials.gov registry record · Phase 1
Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers
A Phase 1 study of TNBC - Triple-Negative Breast Cancer, sponsored by Kari Wisinski.
- Active
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
- 5
- Study locations
NCT03911973: Active Phase 1 study of TNBC - Triple-Negative Breast Cancer, sponsored by Kari Wisinski.
NCT03911973 is a Phase 1 study of TNBC - Triple-Negative Breast Cancer that is active but no longer recruiting, run by Kari Wisinski. The registered enrollment target is 37 participants, below the 480-participant average among 22 other TNBC - Triple-Negative Breast Cancer trials with a reported enrollment target (92% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03911973, a Phase 1 study of TNBC - Triple-Negative Breast Cancer, is active but no longer recruiting, sponsored by Kari Wisinski.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study is designed to determine the RP2D of gedatolisib in combination with talazoparib and to evaluate the efficacy of this combination in advanced HER2 negative breast cancer that is triple negative or BRCA1/2 positive (deficient).
Primary Outcome
Determine the recommended Phase 2 dose (RP2D) of talazoparib in combination with gedatolisib in patients with advanced human epidermal growth factor receptor 2 (HER2) negative (triple negative or BRCA1/2 deficient) breast cancer.
Conditions Studied
Interventions
- DRUG Talazoparib
- DRUG Gedatolisib
Study Locations (5)
Illinois
- Northwestern University Feinberg School of Medicine - Chicago
- University of Illinois Cancer Center - Chicago
Indiana
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center - Indianapolis
Iowa
- University of Iowa Hospital and Clinics - Iowa City
Wisconsin
- University of Wisconsin - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2019-04-17 |
| Est. Completion | 2024-07 |
| Phase | Phase 1 |
What the registry record for NCT03911973 still lists
NCT03911973 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 37 participants, a relatively small participant target, below the 480-participant average among 22 other TNBC - Triple-Negative Breast Cancer trials with a reported enrollment target (92% lower).
The record links to 1 condition, with TNBC - Triple-Negative Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Talazoparib is the first listed.
NCT03911973 lists 5 locations in 4 states (Illinois, Indiana, Iowa).
Frequently Asked Questions
What is clinical trial NCT03911973 about?
NCT03911973 is a clinical study titled "Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers". This study is designed to determine the RP2D of gedatolisib in combination with talazoparib and to evaluate the efficacy of this combination in advanced HER2 negative breast cancer that is triple negative or BRCA1/2 positive (deficient).
What is the current status of trial NCT03911973?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2019-04-17. Estimated completion is 2024-07.
What conditions does trial NCT03911973 study?
This clinical trial studies the following conditions: TNBC - Triple-Negative Breast Cancer.
What interventions are being tested in trial NCT03911973?
The interventions under investigation include: Talazoparib (DRUG), Gedatolisib (DRUG).
Who is sponsoring clinical trial NCT03911973?
This trial is sponsored by Kari Wisinski, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03911973 being conducted?
This trial has 5 study locations across Illinois, Indiana, Iowa, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for TNBC - Triple-Negative Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03911973's enrollment target sits among peer trials
37 15th of 22 higher than 8 of 22 other TNBC - Triple-Negative Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other TNBC - Triple-Negative Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
RECRUITING · Phase 1
-
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Study of LP-184 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02800486 · 37 participants · Phase 2
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- NCT03173937 · 37 participants · Phase 1
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
- NCT03295227 · 37 participants · Phase 1
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
- NCT03401047 · 37 participants · Early Phase 1
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI